PHARMACEUTICAL SOLUTIONS

Counterfeit drugs  became  a nuisance for pharma companies causing drug recalls, liability suits, and jeopardizing brand loyalty as consumers perceive added risks while  employing a  company’s product.  the most important  risk is for consumers as most  of those  fake medicines contain either adulterated active ingredients  which will  put the patient’s lives  in peril  or entirely inert materials  like  chalk or cornstarch rendering the medicines completely inactive. Further, these fake drugs are reprocessed in an unhygienic environment and stored at temperatures without considering the drug’s stability which again threatens the well-being of patients. To circumvent the risks  along side  ensuring patient safety, pharma manufacturers are  arising  with numerous proficient anti-counterfeit strategies. The contemporary methods to combat counterfeiting include legal actions on illicit traders, countermeasures using technologies, consumer education and awareness, private investigations, a

Oral solid dosage (OSD) forms  like  tablets and capsules  still  dominate the pharmaceutical market  because the  most preferred drug delivery system.  whilst  large molecule injectable drugs developed using novel scientific approaches top market charts, small molecule solid dosage products still constitute  a huge  majority  of medicine  and rule the market.  they will  be produced efficiently, are cost-effective, easy to administer and have good storage stability.  they're  widely well-accepted by patients worldwide. When it  involves  approvals of novel drug products, oral solid dose products  still  lead. In 2020, the US FDA’s CDER approved 53 novel drug products and oral solid products accounted for nearly 40 %. And of the 21 newly approved OSD products, 14 were tablets  and seven  were capsules . Drugmakers are adopting lifecycle management approaches  and searching  at different options  to satisfy  patients’ needs with oral solid dosage products. Opportunities  during this

  Patients  lately  are more well-informed than ever.  because of  today’s technological and scientific advances, which have made access to information quick  and straightforward  . With patients and consumers increasingly becoming more empowered, the pharma industry must embrace opportunities to adopt more patient-centred approaches. Beyond the pill Patients now seek holistic health solutions, which are  quite  just the pill and  specialise in  quality, convenience, and cost. Engaging with patients and  taking note of  their voice has become crucial for ensuring future success. Patients are now being recognised as important stakeholders  within the  health care dialogue as regulatory health authorities (such  because the  US Food and Drug Administration and European Medicines Agency EMA) are requesting patient inputs into their  deciding . Patient centricity as  an idea  isn't  new  intrinsically  and has, in fact, been discussed by the pharma industry for years. George W. Mer